THRB and breast cancer: In conclusion, our work revealed at least that TRs are active in BRCA1 associated breast cancer, that TRβ expression in BRCA1 mutant tumor samples is associated with a prolonged overall survival, and that both TRs may arise as interesting alternative targets for endocrine treatment of BRCA1 associated triple negative breast cancer.